Cortexyme, Inc. (CRTX) News
Filter CRTX News Items
CRTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CRTX News Highlights
- CRTX's 30 day story count now stands at 3.
- Over the past 5 days, the trend for CRTX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about CRTX are RARE, DRUG and PATH.
Latest CRTX News From Around the Web
Below are the latest news stories about CORTEXYME INC that investors may wish to consider to help them evaluate CRTX as an investment opportunity.
Quince Therapeutics Details Strategic Growth Plan with Launch of New Corporate NameSOUTH SAN FRANCISCO, Calif., August 01, 2022--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, provided an overview of its strategic growth plan in conjunction with its corporate name change today. The launch of Quince Therapeutics marks a strategic shift in focus as the company prioritizes the clinical development of its highly differentiated bone-targeting drug platform and lead precision |
Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022SOUTH SAN FRANCISCO, Calif., July 27, 2022--Cortexyme, Inc. (Nasdaq: CRTX) today announced that the company’s planned corporate name change to Quince Therapeutics is expected take effect on Monday, August 1, 2022. In conjunction with the corporate name change, the company plans to issue a news release that will provide a business update detailing Quince Therapeutics’ go-forward growth strategy and development pipeline plans. |
Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588SOUTH SAN FRANCISCO, Calif., July 27, 2022--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today reported the successful completion of its Phase 1 single ascending dose and multiple ascending dose (SAD/MAD) clinical trial of COR588, the company’s lysine gingipain inhibitor in development for the treatment of Alzheimer’s disease and indications with disease pathology associated with the keystone path |
Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus InfectionsSOUTH SAN FRANCISCO, Calif., June 21, 2022--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today announced new preclinical data demonstrating the efficacy of the company’s 3CLpro inhibitor, COR803, for treatment of coronavirus infections, including COVID-19 disease, caused by SARS-CoV-2 infection. In ongoing preclinical research, COR803 successfully reduced viral load of SARS-CoV-2 in vivo after ora |
Cortexyme Appoints June Bray to its Board of DirectorsSOUTH SAN FRANCISCO, Calif., June 13, 2022--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on rare and degenerative diseases, today announced the appointment of June Bray, a pharmaceutical industry veteran and global drug development and regulatory process expert, to the company’s Board of Directors. |
Cortexyme Appoints Dr. Philip Low to Its Board of DirectorsSOUTH SAN FRANCISCO, Calif., May 20, 2022--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the appointment of Dr. Philip S. Low, a renowned targeted drug discovery researcher and veteran biotech entrepreneur, to the company’s Board of Directors. |
Cortexyme Successfully Completes Acquisition of NovosteoSOUTH SAN FRANCISCO, Calif., May 20, 2022--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company developing therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the completion of its acquisition of Novosteo, a privately-held biotech company focused on targeted therapeutics to treat rare skeletal diseases, bone cancer and injury. Novosteo stockholders now own approximately 15.5% of the combined company. |
Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic DiseasesSOUTH SAN FRANCISCO, Calif., May 12, 2022--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, announced that the company will participate at The 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases (PgLouisville2022) taking place May 15-17, 2022 in Louisville, Kentucky. Cortexyme’s clinical advisory board member Mar |
Credit Suisse Reaffirms Their Sell Rating on Cortexyme (CRTX)E ratio of…. |
Cortexyme Announces Agreement to Acquire NovosteoSOUTH SAN FRANCISCO, Calif., May 10, 2022--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company dedicated to improving the lives of patients diagnosed with degenerative diseases, today announced that it entered into an agreement under which the company plans to acquire Novosteo, a privately-held biotech company focused on targeted therapeutics to treat rare skeletal diseases, bone cancer and injury. Upon completion of the transaction, Novosteo stockholders will own approxim |